{
    "ticker": "ADVM",
    "name": "Adverum Biotechnologies, Inc.",
    "description": "Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company focused on developing innovative treatments for ocular diseases and other serious conditions. Founded in 2013, Adverum is committed to transforming the treatment landscape for patients through its proprietary AAV-based gene therapy platform. The company's lead product candidate, ADVM-022, is being developed for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME), conditions that can lead to significant vision loss. Adverum's unique approach aims to provide long-lasting therapeutic effects with the potential for a single administration, addressing the need for more effective and convenient treatment options. The company is also exploring applications of its technology in other therapeutic areas, including rare diseases and systemic conditions. With a strong pipeline and a team of experienced professionals, Adverum is poised to make significant contributions to the field of gene therapy, enhancing patient outcomes and improving quality of life.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Menlo Park, California, USA",
    "founded": "2013",
    "website": "https://www.adverum.com",
    "ceo": "Laurie Heilmann",
    "social_media": {
        "twitter": "https://twitter.com/AdverumBio",
        "linkedin": "https://www.linkedin.com/company/adverum-biotechnologies"
    },
    "investor_relations": "https://investors.adverum.com",
    "key_executives": [
        {
            "name": "Laurie Heilmann",
            "position": "CEO"
        },
        {
            "name": "Michael A. McGarrity",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapy",
            "products": [
                "ADVM-022"
            ]
        }
    ],
    "seo": {
        "meta_title": "Adverum Biotechnologies, Inc. | Gene Therapy for Ocular Diseases",
        "meta_description": "Learn about Adverum Biotechnologies, a leader in gene therapy for treating ocular diseases like wet AMD and DME. Explore innovative treatments and research.",
        "keywords": [
            "Adverum",
            "Gene Therapy",
            "Ocular Diseases",
            "Wet AMD",
            "Diabetic Macular Edema",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What is Adverum Biotechnologies known for?",
            "answer": "Adverum Biotechnologies is known for its innovative gene therapy treatments for ocular diseases."
        },
        {
            "question": "Who is the CEO of Adverum?",
            "answer": "Laurie Heilmann is the CEO of Adverum Biotechnologies, Inc."
        },
        {
            "question": "Where is Adverum headquartered?",
            "answer": "Adverum is headquartered in Menlo Park, California, USA."
        },
        {
            "question": "What are Adverum's main products?",
            "answer": "Adverum's main product candidate is ADVM-022 for the treatment of wet AMD and DME."
        },
        {
            "question": "When was Adverum founded?",
            "answer": "Adverum was founded in 2013."
        }
    ],
    "competitors": [
        "AVPT",
        "PFE",
        "REGN",
        "AMGN"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}